Vulvodynia

Table of Contents

1. Overview and Definition
2. Classification: Provoked vs Generalized
3. Causes and Contributing Factors
4. Symptoms
5. Diagnosis
6. Pelvic Floor Dysfunction
7. Topical and Local Treatments
8. Systemic Treatments
9. Low-Oxalate Diet and Lifestyle
10. Vestibulectomy
11. Psychosexual Impact and Support
12. Prognosis
13. Key Research Papers
14. Connections
15. Featured Videos

Overview and Definition

Vulvodynia is a chronic vulvar pain disorder lasting at least 3 months, without an identifiable cause on examination or laboratory testing that would fully explain it. It is defined by the International Society for the Study of Vulvovaginal Disease (ISSVD) as vulvar pain of at least 3 months' duration, in the absence of relevant visible findings or a specific, clinically identifiable neurological disorder.

Vulvodynia affects an estimated 8–16% of women at some point in their lives, making it one of the most common causes of vulvar pain — yet it remains profoundly underdiagnosed and undertreated. The average woman with vulvodynia sees three or more healthcare providers before receiving a correct diagnosis, and is told by many that "nothing is wrong" or the pain is psychological. Vulvodynia is a real, physical condition with identifiable neurobiological, musculoskeletal, and hormonal contributors.

The name derives from the Latin vulva and Greek odyne (pain). Historical terms including "vulvodynia" (as a catch-all), "vulvar vestibulitis syndrome," and "essential vulvodynia" have been standardized by the ISSVD into a classification by site (localized vs. generalized) and provocation (provoked vs. spontaneous vs. mixed).

Classification: Provoked vs Generalized

The ISSVD 2015 classification organizes vulvodynia along two axes: anatomical site and stimulus relationship.

By Anatomical Site

• Localized vulvodynia — pain confined to a specific area: most commonly the vestibule (the tissue surrounding the vaginal opening), also the clitoris (clitorodynia), or the left or right hemivulva
• Generalized vulvodynia — pain distributed across the entire vulva without a clear focal point

By Stimulus Relationship

• Provoked vulvodynia (PVD) / Vestibulodynia — pain that occurs only in response to physical contact or pressure (touch, intercourse, tampon insertion, bicycle riding, prolonged sitting, tight clothing). By far the most common subtype, affecting 90% of women diagnosed with vulvodynia. The vestibule is almost always the primary pain site. Also called provoked vestibulodynia (PVD), formerly "vulvar vestibulitis syndrome."
• Spontaneous vulvodynia — constant or near-constant burning, stinging, or aching pain without a triggering touch. More common in older women and in the context of generalized distribution.
• Mixed vulvodynia — components of both provoked and spontaneous pain.

Primary vs Secondary PVD

• Primary PVD — pain present from the first attempted intercourse or tampon use; the patient has never been pain-free with penetration
• Secondary PVD — pain developed after a period of pain-free sexual activity; more commonly linked to hormonal changes (oral contraceptive use, postpartum estrogen drop), recurrent yeast infections, or triggering events

Causes and Contributing Factors

Vulvodynia is almost certainly multifactorial, with different contributors playing different roles in different women. No single cause has been established, and the disorder is best understood as a central and peripheral pain sensitization syndrome with several entry points.

Neuroproliferative / Peripheral Sensitization

• Women with PVD have a significantly higher density of sensory nerve fibers (particularly C-fibers expressing substance P and CGRP) in the vestibular epithelium compared to controls — a form of neuroproliferation driven by chronic mast cell activation and local inflammatory cytokines
• Lowered pain thresholds (allodynia — pain from normally non-painful stimuli; hyperalgesia — amplified pain from painful stimuli) reflect peripheral sensitization of these excess nerve fibers

Hormonal Factors

• Combined oral contraceptives (COCs) — particularly low-dose progestin formulations — reduce free testosterone and increase sex hormone-binding globulin (SHBG), causing vestibular atrophy, reduced lubrication, and increased sensitivity; starting COCs in adolescence (before the vulva has fully matured hormonally) is a recognized risk factor for secondary PVD
• Postpartum estrogen deficiency — breastfeeding suppresses estrogen to near-menopausal levels; vulvar atrophy and provoked pain after delivery are common
• Perimenopause and menopause — genitourinary syndrome of menopause (GSM) causes vulvar atrophy, loss of elasticity, and increased pain with contact; distinguishing GSM from vulvodynia requires careful examination

Pelvic Floor Dysfunction

• Hypertonic (overactive) pelvic floor muscles — a near-universal finding in PVD; the chronic guarding response to anticipated pain creates a vicious cycle: pain triggers muscle bracing, bracing causes pain
• Trigger points in the levator ani, obturator internus, and piriformis muscles refer pain to the vestibule and perineum

Genetic and Immune Factors

• Polymorphisms in the IL-1 receptor antagonist gene increase local inflammatory response to Candida and other vaginal pathogens, predisposing to vestibular inflammation and nerve sensitization
• Altered TLR2 and TLR4 expression in vestibular fibroblasts from women with PVD suggests an exaggerated innate immune response to commensal organisms

Recurrent Candidal Vulvovaginitis

• Repeated yeast infections — particularly with prolonged antifungal treatment — can trigger and perpetuate vestibular nerve sensitization; many women date the onset of PVD to a first or recurrent yeast infection

Central Sensitization

• Many women with vulvodynia have comorbid conditions characteristic of central sensitization: fibromyalgia, interstitial cystitis/painful bladder syndrome, temporomandibular disorders, irritable bowel syndrome, chronic headaches
• fMRI studies show altered pain processing in brain regions including the insula and anterior cingulate cortex

Symptoms

• Burning — the most characteristic description; often described as a raw, stinging, or scalded sensation
• Stinging or cutting pain — particularly with penetration or touch
• Rawness — feeling as though the skin has been abraded or scraped
• Provoked pain — dyspareunia (painful intercourse), pain with tampon insertion, gynecological exams, bike riding, tight-waistband clothing, prolonged sitting
• Aching or throbbing — may persist for hours or days after provocation in PVD; the hallmark "after-burn"
• Itching — less common; usually secondary to neurogenic itch rather than infection
• Secondary vaginismus — involuntary contraction of pelvic floor muscles in anticipation of painful penetration; may develop after months or years of painful intercourse

Diagnosis

Vulvodynia is a diagnosis of exclusion: identifiable causes of vulvar pain must be ruled out before the diagnosis is made. The clinical workup includes:

History

• Duration, location, quality, and triggers of pain
• Relationship to menstrual cycle, hormonal medications, pregnancy
• Sexual history including onset of pain in relation to first intercourse
• Gynecological history: yeast infections, STIs, prior vulvar biopsies or surgeries
• Comorbid conditions: interstitial cystitis, IBS, fibromyalgia, anxiety, depression

Physical Examination

• External inspection — normally unremarkable in vulvodynia; erythema of the vestibule may be present but is non-specific
• Cotton-swab test (Q-tip test) — light touch with a cotton-tipped swab applied to the posterior vestibule (5 and 7 o'clock positions) and the labial minora; a pain score of 5–10 out of 10 on vestibular touch with no or minimal pain elsewhere is the hallmark finding of PVD; the test maps the pain distribution
• Pelvic floor assessment — external and internal palpation of levator ani, obturator internus, and piriformis for hypertonicity and trigger points
• Speculum exam — if tolerated; assesses for vulvar skin changes (lichen sclerosus, lichen planus), atrophy, or discharge

Laboratory Testing

• Vaginal pH and wet prep — to exclude bacterial vaginosis and Trichomonas
• Vaginal culture for Candida (speciation matters — Candida glabrata responds differently to azoles than C. albicans)
• STI testing (chlamydia, gonorrhea) as appropriate
• Hormone levels (FSH, estradiol, total and free testosterone) in women on hormonal contraceptives or with atrophic changes

Conditions to Exclude

• Lichen sclerosus, lichen planus, contact dermatitis, psoriasis (skin biopsy if indicated)
• Active candidal or bacterial vaginosis infection
• Genitourinary syndrome of menopause (atrophic vaginitis)
• Pudendal neuralgia (differentiated by positional component — worse sitting, relieved standing; extends to perineum and rectum)
• Vulvar intraepithelial neoplasia (VIN) — biopsy any suspicious lesions

Pelvic Floor Dysfunction

Pelvic floor physical therapy (PT) is the single most evidence-backed first-line treatment for PVD, with a 50–80% response rate in randomized and observational studies. The hypertonic pelvic floor found in most women with PVD is both a consequence of chronic pain and a perpetuating cause — making PT essential regardless of which other treatments are used.

• What pelvic PT involves: external and (with consent) internal manual therapy of the pelvic floor muscles, connective tissue mobilization, myofascial release, trigger point pressure, biofeedback, and home exercises including paradoxical relaxation (learning to release rather than contract the pelvic floor)
• Biofeedback — surface electromyography (sEMG) or manometry provides real-time visual feedback on pelvic floor muscle tension; patients learn to identify and reduce involuntary baseline hypertonicity; particularly effective when combined with manual therapy
• Dilators — graduated vaginal dilators used at home promote progressive desensitization and pelvic floor relaxation; typically introduced after the pelvic floor is partially relaxed through manual therapy
• Botulinum toxin (Botox) injections — for refractory pelvic floor hypertonicity; injected into the bulbocavernosus and pubococcygeus muscles under EMG guidance; randomized data show modest but significant reductions in dyspareunia in women with PVD; duration of effect 3–6 months; repeat injections are often required
• Finding a pelvic PT — the American Physical Therapy Association's Academy of Pelvic Health directory and the National Vulvodynia Association referral list are the most reliable resources in the US; an ideal therapist has specific postgraduate training in pelvic floor disorders and experience with vulvodynia

Topical and Local Treatments

• Topical lidocaine — 2% lidocaine gel or 5% ointment applied to the vestibule 30 minutes before intercourse and up to 4 times daily; reduces provoked pain acutely; nightly lidocaine application at low concentration (2%) has been shown in a randomized trial to desensitize vestibular nerves over 3–7 months
• Topical estrogen or estrogen-testosterone cream — particularly effective in secondary PVD associated with hormonal contraceptive use or postpartum/perimenopausal estrogen deficiency; applied directly to the vestibule nightly; restores vestibular tissue trophicity; often combined with discontinuing the offending combined oral contraceptive
• Topical testosterone — 2% testosterone propionate in petroleum jelly applied to the vestibule; increases vestibular androgen receptor stimulation; some evidence for benefit when combined with topical estrogen in OCP-associated PVD
• Topical cromolyn sodium — mast cell stabilizer; reduces mast cell degranulation and local neurogenic inflammation in the vestibule; available compounded at 4%
• Capsaicin — depletes substance P from C-fibers; 0.025% applied to the vulva nightly in small studies showed benefit but is poorly tolerated due to initial burning; not widely used
• Compounded baclofen + diazepam suppositories — vaginal or rectal use; relaxes internal pelvic floor smooth and striated muscle; most useful as adjunct to pelvic PT for hypertonic pelvic floor

Systemic Treatments

• Tricyclic antidepressants (TCAs) — amitriptyline and nortriptyline (10–150 mg nightly) reduce neuropathic pain by inhibiting sodium channels and norepinephrine-serotonin reuptake; sedating side effects make nighttime dosing practical; nortriptyline is better tolerated than amitriptyline
• SNRIs (duloxetine, venlafaxine) — comparable neuropathic pain mechanism to TCAs; duloxetine 30–120 mg daily; often better tolerated than TCAs in terms of anticholinergic burden; preferred when comorbid depression or fibromyalgia is present
• Gabapentinoids (gabapentin, pregabalin) — reduce central sensitization by inhibiting voltage-gated calcium channels; gabapentin 300–3600 mg/day in divided doses; topical gabapentin 6% (compounded) applied locally is an alternative to reduce systemic side effects (dizziness, weight gain, cognitive fog)
• Oral contraceptive discontinuation — in women who developed PVD on COCs, stopping the pill and transitioning to non-hormonal contraception or progestin-only (Mirena IUD) with local estrogen supplementation resolves or significantly improves symptoms in a meaningful subset; SHBG levels normalize over 3–6 months
• Low-dose naltrexone — 1.5–4.5 mg nightly; emerging evidence for central sensitization conditions including vulvodynia; reduces neuroinflammation via Toll-like receptor 4 modulation; not yet first-line but increasingly used off-label
• Antihistamines — hydroxyzine 25–75 mg at bedtime; reduces mast cell-mediated vestibular inflammation; particularly useful when itching or burning is associated with histamine-type reactions or when symptoms worsen with foods high in histamine

Low-Oxalate Diet and Lifestyle

The low-oxalate diet for vulvodynia is based on the hypothesis that urinary oxalate crystals irritate the vestibular tissue, contributing to pain. While the mechanism remains debated and evidence is observational rather than from randomized trials, many women report symptom relief. The diet is nutritionally safe when managed carefully.

• High-oxalate foods to reduce: spinach, beets, Swiss chard, rhubarb, soy products, nuts and nut butters (especially almonds and peanuts), wheat bran, black tea, dark chocolate, sweet potatoes, and most berries
• Low-oxalate alternatives: kale, cauliflower, broccoli, cabbage, peas, mushrooms, green beans, white rice, pasta, poultry, fish, eggs, dairy (calcium binds oxalate in the gut and reduces absorption)
• Calcium citrate supplementation — 200–400 mg with meals; calcium citrate (unlike calcium carbonate) binds dietary oxalate in the gut before absorption, reducing urinary oxalate; some practitioners recommend this as primary intervention over strict dietary restriction
• Hydration — adequate fluid intake (at least 2 liters daily) dilutes urinary oxalate concentration
• Vulvar hygiene — avoid perfumed soaps, bubble baths, detergents with optical brighteners; use unscented glycerin-free soap or plain water for vulvar cleansing; wear breathable cotton underwear; avoid pantiliners with synthetic fibers (oxalate irritation hypothesis applies here too)
• Lubricants — silicone-based lubricants are preferred over water-based (which often contain glycerin or propylene glycol, potential irritants); avoid any lubricant with flavoring, warming agents, or antimicrobials

Vestibulectomy

Vestibulectomy — specifically modified posterior vestibulectomy with vaginal advancement — is a surgical procedure that removes the hypersensitive, nerve-dense vestibular tissue and advances the vaginal mucosa to cover the defect. It is indicated for localized PVD that has failed conservative management (pelvic PT, topical/systemic medications) for at least 6 months.

• Who is a candidate: women with well-localized PVD (positive cotton-swab test focused on the posterior vestibule), whose pain is predominantly provoked (not spontaneous), who have completed adequate trials of pelvic PT and topical therapy, and who have no active infection or untreated pelvic floor hypertonicity
• Procedure: under general or regional anesthesia, the affected vestibular tissue (typically the posterior vestibule from 3 to 9 o'clock, including the hymeneal ring) is excised; the vaginal mucosa is advanced and sutured to the perineal skin; minor superficial glands may be removed; the procedure takes 30–60 minutes
• Outcomes: the most effective treatment for refractory PVD with success rates of 60–90% in carefully selected patients; the 2016 NVA-funded Harlow et al. RCT found vestibulectomy superior to both biofeedback and cognitive-behavioral therapy at 6 months
• Recovery: 4–6 weeks of pelvic rest; graduated dilator use begins at 6 weeks; pelvic PT is recommended concurrently to address any residual pelvic floor hypertonicity; full recovery and return to pain-free intercourse typically takes 3–6 months
• Risks: infection, hematoma, scarring, change in perineal appearance, rare worsening of pain (especially when pelvic floor hypertonicity is not addressed), altered sensation (usually temporary)
• Prerequisite: pelvic floor hypertonicity must be treated concurrently or pre-operatively — vestibulectomy will not succeed if severe pelvic floor muscle dysfunction persists

Psychosexual Impact and Support

Vulvodynia profoundly affects sexuality, relationships, and mental health. The psychosexual impact is not a cause of vulvodynia but an important comorbidity that, if unaddressed, perpetuates the pain cycle.

• Depression and anxiety — affect approximately 40–60% of women with vulvodynia; pain-related mood disturbance is independent of whether pain is the primary cause or effect; both must be treated
• Relationship strain — avoidance of sexual activity due to pain strains intimacy and communication; partners may misinterpret pain-driven avoidance as rejection; couples counseling significantly improves outcomes in randomized studies
• Fear-avoidance model — anticipation of pain leads to anxiety, hypervigilance, and muscle bracing before touch occurs; the brain encodes pain responses that then fire before physical contact; cognitive-behavioral therapy (CBT) specifically targeting pain catastrophizing and fear-avoidance is a validated psychological intervention for vulvodynia
• Mindfulness-based therapy — mindfulness for vulvodynia programs (8-week protocols adapted from mindfulness-based stress reduction) reduce pain intensity, sexual distress, and catastrophizing in randomized trials; improve central pain modulation
• Sex therapy — with a certified sex therapist familiar with vulvodynia; focuses on graduated sensate focus exercises, non-penetrative intimacy, communication skills, and reframing sexuality outside penetration
• Online communities and peer support — the National Vulvodynia Association (NVA) and online forums provide community for a condition marked by isolation and medical dismissal; validated peer support is protective against depression

Prognosis

Vulvodynia is a treatable condition — not a life sentence of pain. Prognosis is strongly related to access to informed, multidisciplinary care.

• Approximately 50–70% of women with PVD achieve significant or complete pain resolution with multimodal treatment (pelvic PT + topical treatment + psychological support); vestibulectomy raises this to 60–90% in the surgical subgroup
• A population-based cohort study (Reed et al., 2012) found that over a 5-year period, 51% of women with vulvodynia experienced resolution without surgical intervention — suggesting that natural history includes significant spontaneous improvement, though waiting without treatment prolongs suffering
• Women who receive care from specialists familiar with vulvodynia (urogynecologists, vulvologists, experienced pelvic PTs, sex therapists) have meaningfully better outcomes than those receiving only primary care
• Comorbid central sensitization conditions (fibromyalgia, interstitial cystitis, IBS) require concurrent management and may limit response to local vulvar treatments alone; systemic neuropathic pain agents are more likely to be needed in this subgroup
• The most important prognostic message for patients: this is real, it is physical, effective treatments exist, and persistence through the treatment ladder pays off

Key Research Papers

1. Bornstein J, Goldstein AT, Stockdale CK, et al. 2015 ISSVD, ISSWSH and IPPS Consensus Terminology and Classification of Persistent Vulvar Pain and Vulvodynia. Obstetrics & Gynecology. 2016;127(4):745–751. PMID 26962904.
2. Reed BD, Harlow SD, Sen A, Legocki LJ, Edwards RM, Haefner HK, Helmuth ME. Prevalence and Demographic Characteristics of Vulvodynia in a Population-Based Sample. American Journal of Obstetrics & Gynecology. 2012;206(2):170.e1–9. PMID 21963300.
3. Harlow BL, Stewart EG. A Population-Based Assessment of Chronic Unexplained Vulvar Pain: Have We Underestimated the Prevalence of Vulvodynia? Journal of the American Medical Women's Association. 2003;58(2):82–88. PMID 12568187.
4. Goldstein AT, Pukall CF, Brown C, Bergeron S, Stein A, Kellogg-Spadt S. Vulvodynia: Assessment and Treatment. Journal of Sexual Medicine. 2016;13(4):572–590. PMID 26944462.
5. Bergeron S, Binik YM, Khalife S, et al. A Randomized Comparison of Group Cognitive-Behavioral Therapy, Surface Electromyographic Biofeedback, and Vestibulectomy in the Treatment of Dyspareunia Resulting from Vulvar Vestibulitis. Pain. 2001;91(3):297–306. PMID 11275387.
6. Pukall CF, Goldstein AT, Bergeron S, et al. Vulvodynia: Definition, Prevalence, Impact, and Pathophysiological Factors. Journal of Sexual Medicine. 2016;13(3):291–304. PMID 27045255.
7. Goldstein AT, Belkin ZR, Krapf JM, et al. Polymorphisms of the Androgen Receptor Gene and Hormonal Contraceptive Induced Provoked Vestibulodynia. Journal of Sexual Medicine. 2014;11(11):2764–2771. PMID 25065598.
8. Landry T, Bergeron S, Dupuis MJ, Desrochers G. The Treatment of Provoked Vestibulodynia: A Critical Review. Clinical Journal of Pain. 2008;24(2):155–171. PMID 18209525.
9. Haefner HK, Collins ME, Davis GD, et al. The Vulvodynia Guideline. Journal of Lower Genital Tract Disease. 2005;9(1):40–51. PMID 15870521.
10. Bohm-Starke N, Hilliges M, Falconer C, Rylander E. Increased Intraepithelial Innervation in Women with Vulvar Vestibulitis Syndrome. Gynecologic and Obstetric Investigation. 1998;46(4):256–260. PMID 9813380.
11. ter Kuile MM, van Lankveld JJ, de Groot HE, Melles R, Neffs J, Zandbergen M. Cognitive-Behavioral Therapy for Women with Lifelong Vaginismus: Process and Prognostic Factors. Behaviour Research and Therapy. 2007;45(2):359–373. PMID 16793011.
12. Brauer M, ter Kuile MM, Laan E. Effects of Appraisal of Sexual Stimuli on Sexual Arousal in Women with and without Superficial Dyspareunia. Archives of Sexual Behavior. 2009;38(4):476–485. PMID 19554449.

PubMed Topic Searches

• PubMed — vulvodynia
• PubMed — provoked vestibulodynia
• PubMed — vulvar vestibulitis syndrome
• PubMed — vulvodynia pelvic floor therapy
• PubMed — vestibulectomy dyspareunia
• PubMed — low oxalate diet vulvodynia
• PubMed — vulvodynia tricyclic antidepressants
• PubMed — pelvic floor dysfunction dyspareunia
• PubMed — vulvodynia oral contraceptive
• PubMed — vulvar pain central sensitization

Back to Table of Contents

Connections

• Bacterial Vaginosis
• Endometriosis
• Infertility
• Ectopic Pregnancy
• Menopause and HRT
• Ovarian Cysts
• PMS and PMDD
• Preeclampsia
• Uterine Fibroids
• Yeast Infections
• Pelvic Inflammatory Disease
• Reproductive Medicine Index
• Chronic Pain
• Irritable Bowel Syndrome
• Interstitial Cystitis
• Vitamin D3

Back to Table of Contents

×

Featured Videos